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Background: The mechanisms underlying the influence of sex hormones in multiple
sclerosis (MS) are uncertain. Sex steroids interact with cholesterol metabolism and
the serum lipid profile has been associated with the severity of the disease. We
hypothesized that the putative associations between lipoprotein metabolism and MS
could be modulated by sex steroids exposure. The aim of this study was to investigate
whether oral contraceptives (OC) use changes the lipoprotein profile associated with
disability in patients with multiple sclerosis.
Methods: Clinical data was collected from 133 relapsing-remitting multiple sclerosis
(RRMS) women with a mean of 6.5 years of disease duration and prior to the start of
disease-modifying therapies. Patients whowere using OC after disease onset (DO) (OC+,
n= 57) were compared to those who never used OC or discontinued its intake before DO
(OC–, n = 76). In both cohorts of subjects, the associations between the apolipoprotein
E (ApoE) polymorphism, and plasma lipid levels, and the annualized relapse rate (RR),
the Expanded Disability Status Score (EDSS), and the Multiple Sclerosis Severity Score
(MSSS) were evaluated using a hierarchic multiple regression analysis after adjustment
for confounders.
Results: Low density lipoprotein (LDL) levels were associated with higher EDSS
(p = 0.010) and MSSS (p = 0.024) in the whole studied cohort. In E3/E3 phenotype
carriers (73.7%), EDSS and MSSS were lower in OC+ in comparison with OC– subgroup
of patients (p < 0.01). LDL and total cholesterol were associated with EDSS (p = 0.005
and p = 0.043, respectively), and LDL and the triglyceride/high density lipoprotein ratio
with MSSS (p = 0.011 and p = 0.048, respectively) in OC+ patients. In OC– subgroup
of patients, ApoE levels were associated with EDSS (p = 0.012) and MSSS (p = 0.031).
No significant interactions between the lipid variables or OC use and RR were observed.
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Conclusions: Serum lipid profile is associated with protective effects of OC use on
disability of RRMS patients. Lipoprotein metabolism may be involved in the modulatory
effects of sex steroids on the severity of the disease.
Keywords: multiple sclerosis, lipoproteins, cholesterol, apolipoprotein E, oral contraceptives, sex steroids
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory demyelinating and
neurodegenerative disease in which onset and course may be
modulated by gender and sex hormones (1). The mechanisms
underlying sex differences and effects of sex steroids in the
disease are poorly understood. Recent studies have implicated
serum cholesterol metabolism and lipoprotein profile in the
pathophysiology and severity of the disease (2). Nevertheless,
results are mixed, and whether these relations are causal or
secondary to the disease process, treatment regimens or other
confounding factors remain uncertain. Complex interactions
between cholesterol metabolism and sex steroids are well-known
(3) and may modulate the clinical activity of experimental
autoimmune encephalomyelitis (EAE), the animal model for MS
(4, 5). Therefore, we hypothesized that the putative associations
between lipoprotein metabolism and the severity of MS could be
modulated by sex hormone exposure.
Oral contraceptives (OC) use has provided an opportunity
to assess the influence of sex hormones on the risk and course
of MS. Recent data suggested a less severe clinical course (6,
7) and decreased inflammatory brain lesions (8) in relapsing-
remitting (RRMS) women taking OC. Protective effects of estriol,
the estrogen unique to parity (9), and of hormone therapy in
postmenopausal MS women were also reported (10). In healthy
women, OC use induces variable alterations in serum lipids and
apolipoproteins levels modulated by ApoE polymorphism (11,
12). Although ApoE polymorphism is not generally considered
to affect the risk ofMS, its association with the neurodegenerative
process and severity of the disease is still controversial (4, 5).
ApoE is implicated in the immune dysfunction and clinical
activity of EAE (5) and recent studies have suggested that EAE
disease severity is differently modulated by cholesterol and ApoE
metabolism in female and male mice (4, 13). Oestrogens may
regulate the expression of ApoE gene (2) and estrogen treatment
has protective effects in EAE (14). Oestrogens-ApoE interactions
are suggested to be involved in other neurological conditions
with a sex bias and abnormal cholesterol metabolism, such as
Alzheimer disease (15). Based on these data, the aim of the
present study was to investigate whether OC intake in RRMS
patients influence the associations between the serum lipoprotein
profile and the clinical severity of the disease.
MATERIALS AND METHODS
Study Population
The studied population include 133 women with the diagnosis of
RRMS according to the revised McDonald criteria (16) followed
at the MS outpatient clinic of a University Hospital in Lisbon
(Portugal). Most women enrolled in this study belong to a
population of Caucasian origin included in a previous work
published by our group (7). The present study includes all
patients followed in our clinic since 1995 diagnosed with RRMS
with at least 2 years of disease duration and whose lipid data
were available prior to the start of disease-modifying therapies.
No woman was taking lipid-lowering agents. Disease onset (DO)
was defined as the age of appearance of the first symptoms
suggestive of MS. The annualized relapse rate (RR) and the
Expanded Disability Status Scale (EDSS) and Multiple Sclerosis
Severity (MSSS) values were determined at a stable phase of
the disease. MSSS scores were obtained from Figure 3 of the
paper of Roxburg et al. (17). The MSSS is based on EDSS scores
adjusted for disease duration and it is a method to compare
disability progression in groups of patients (7, 17). Women in
menopause or history of gynecological surgical interventions or
a delivery the last 6 months were excluded. Clinical indexed
information included the body mass index (BMI) (Kg/m2), age of
first menstruation (menarche) and history of childbirths (parity),
smoking habit, and OC intake. Patients labeled smokers reported
to smoke regularly at least five cigarettes per day since DO.
Women were classified as OC non-users if they never used OC
or discontinued its intake for at least 1 year before DO (OC–);
and OC users if they maintained pill intake after DO for at least
a continuous period of 1 year (OC+). We were unable to take
the composition of the prescribed pill into account because this
information was lacking for some patients and many changed
the brand of the drug. However, all women who remembered
the formulation of OC used took formulations of 20 or 30 µg of
ethinyl estradiol combined with progestin. No woman reported
to use progestin-only formulations. This study was approved by
the Ethics Committee of the Centro Hospitalar, Lisboa Central
(Lisbon, Portugal). All patients gave written informed consent,
including for publication of results, in accordance with the
Declaration of Helsinki.
Biochemical Analysis
Blood samples were collected in fasting conditions shortly after
clinical data collection and neurological examination. Plasma
or serum samples were stored at −80◦C and biochemical
measurements performed in blind conditions regarding subject
participants. At sampling, patients were in a remission phase
of RRMS and none of them had initiated disease-modifying
therapies, suffered from a relapse or were treated with steroids for
at least 1 month. Serum triglycerides (TG), total cholesterol (TC),
high density lipoprotein (HDL)-cholesterol, apolipoprotein A-1
(ApoA1), and apolipoprotein B (ApoB) were determined with
enzymatic methods and lipoprotein (a) [Lp(a)] by turbidimetric
immunoassay by using a Hitachi 911 autoanalyzer and
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commercial kits (Roche Diagnostic, Mannheim, Germany). Non-
HDL cholesterol levels were calculated by subtracting HDL from
TC. Low density lipoprotein (LDL)-cholesterol was determined
by using the Friedewald equation (18) and oxidized LDL
(oxLDL) by Enzyme-Linked Immunosorbent Assay (Mercodia,
eBioscience). Apolipoprotein E (ApoE) protein levels were
determined by electroimmunodiffusion (Sebia, Emery, France)
and ApoE polymorphism examined by using an isoelectric
focusing (IEF) method as described previously (19). Briefly,
15 µl of delipidated plasma samples was run on agarose
with sorbitol, urea, ampholine (pH 5–7) and pharmalyte
(pH 4–6.5) (Amersham Pharmacia Biotech, Little Chalfont,
UK). After IEF, the proteins were transferred to nitrocellulose
membranes (Immobilon, pore size 0.2µm; Millipore Corporate
Headquarters, Billerica, USA). The membranes were incubated
with polyclonal-goat anti-human ApoE antibody (Daichi Pure
Chemicals, Tokyo, Japan) and IgG peroxidase-conjugate anti-
goat antibody (Sigma-Aldrich Biotechnology, St Louis, USA).
The ApoE isoforms were visualized in a solution containing
3,3’ diaminobenzidine tetrahydrochloride reagent (Sigma). For
common ApoE polymorphism, protein phenotyping is in good
agreement with DNA-based genotyping (20).
Statistical Analysis
Patient demographic and clinical characteristics were described
using mean, median, standard deviation, and interquartile range
for continuous variables. In the text, standard deviation is
presented as mean (standard deviation). For categorical variables
absolute and relative frequencies were calculated. The relation
between severity parameters of clinical disease activity (RR,
MSSS, and EDSS) and ApoE phenotypes was evaluated using
Kruskal-Wallis ranking test. Comparisons of disease severity
between OC+ and OC– subgroups of patients were performed
using a Mann Whitney test. The associations between disease
severity parameters such as MSSS, EDSS, and RR and the lipid
profile were evaluated using a two tailed Spearman Correlation
analysis. The correlation analysis was performed for the total
subset of patients carrying the E3/E3 phenotype and also split for
those in OC+ and OC– subgroups. A hierarchical multiple linear
regression was used assuming the EDSS and MSSS as dependent
variables and characterization variables such as age, disease
onset, oral contraception, disease duration and parity (block
1), and lipid profile parameters that had significant correlation
with EDSS and MSSS in the correlation analysis (block 2), as
independent variables. A enter model was used for the variables
in the block 1 and a stepwisemodel was used for variables in block
2.A significance level of 0.05 was considered in all analysis.
RESULTS
The main demographic and clinical characteristics of the studied
population are summarized in Table 1. Twenty-nine patients
(21.8%) were classified as overweight (25 ≥ BMI < 30) or
obese (BMI ≥ 30). In the OC+ subgroup (n = 57), the mean
duration of OC use was 10 years (6.6) and all but nine women
started intake before DO. In the OC– subgroup, fifty patients
were never prescribed with OC and 26 discontinued the intake
before DO. OC+ patients were younger and had the onset of
the disease at an earlier age than OC– subgroup of patients.
Significant associations were found between EDSS andMSSS and
age (p < 0.001 and p = 0.013), DO (p = 0.004 and p < 0.001),
disease duration (p = 0.004 and p < 0.001), OC use (p = 0.001
and p = 0.002), and parity after DO (p < 0.001 and p = 0.006).
RR was only associated with disease duration (p = 0.006).
Menarche age, duration of OC intake, BMI, and smoker habit
were not associated with RR or disability scores (data not shown).
Concerning the lipid data, HDL and Apo A1 levels were higher
in OC+ patients. In a hierarchic multiple regression analysis
adjusted for age, DO, disease duration, and OC use, LDL was the
only lipid variable associated with EDSS and MSSS (β = 0.008,
95% CI (0.002 to 0.015) p = 0.010 and β = 0.013, 95% CI
(0.002 to 0.025) p = 0.024, respectively). ApoE phenotypes
found in the studied cohort were E3/E3 (n = 98, 73.7%),
E4/E3 (n = 20, 15%), E2/E3 (n = 12, 9%). Analysis of ApoE
polymorphism was missing from one patient and two additional
patients carried the E4/E2 phenotype. No homozygotes for the
E4 and E2 alleles were detected. The observed frequencies of
ApoE alleles were comparable with those reported for the general
populations in Portugal and other countries in South Europe
(21).
No associations between the three common ApoE phenotypes
and EDSS, MSSS, or RR were found. However, in the E3/E3
subset of subjects, EDSS, and MSSS values were lower in OC+ in
comparison to OC– subgroup of patients (p < 0.01) (Figure 1).
These results remain significant after hierarchical multiple linear
regression analysis adjusting for demographic features among
the ApoE genetic groups. RR was not significantly changed
by OC intake (p = 0.457). In consequence, serum lipid and
apolipoprotein levels were investigated in this subset of patients
according to OC use. Overall, there was no statistical difference
in the lipid profile with the exception of higher ApoA1 and
lower ApoE levels in OC+ in comparison to OC– patients [171.3
mg/dl (40.6) vs. 151.5 mg/dl, (27.5); p < 0.01 and 67.3 mg/dl
(29.6) vs. 80.1 mg/dl (28.7); p < 0.05, respectively]. Correlation
between lipoprotein levels and disability scores were analyzed in
E3/E3 subset of patients stratified according to OC use. In OC+
subgroup of patients, LDL was associated with EDSS (p= 0.018)
and ApoB was associated with MSSS (p = 0.043). In contrast, in
the OC– subgroup of patients, ApoE was associated with MSSS
values (p= 0.008); TC and non-HDL were associated with EDSS
(p= 0.025 and p= 0.035, respectively); and TC (p= 0.035), LDL
(p = 0.028), non-HDL (p = 0.005), and ApoB (p = 0.008) with
RR (Table 2).
A hierarchic multiple regression analysis in E3/E3 subjects
split for OC+ and OC– patients and adjusted for age, DO and
disease duration was then performed (Table 3). EDSS was related
to LDL [β = 0.026, 95% CI (0.009 to 0.044); p = 0.005] and
TC [β = −0.018, 95% CI (−0.034 to −0.001); p = 0.043];
model R square = 0.328 (p = 0.015) in OC+ population; and
to ApoE [β = 0.015, 95% CI (0.004 to 0.028); p = 0.012];
model R square = 0.312 (p = 0.001) in the OC– subgroup
of patients. In a similar model, MSSS was related to LDL,
[β = 0.022, 95% CI (0.002 to 0.033); p = 0.011] and to
TG/HDL ratio, [β = 0.389, 95% CI (0.088 to 0.800); p = 0.048];
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TABLE 1 | Patient demographic and clinical characteristics.
Characteristics Total (n = 133) OC+
(n = 57)
OC–
(n = 76)
p-value
Age (years) 35.2 ± 8.4 32.4 ± 6.9 37.3 ± 8.8 0.001
Disease onset (age) 28.6 ± 8.2 25.7 ± 6.7 30.8 ± 8.5 <0.001
Disease duration (years) 6.5 ± 5.3 6.6 ± 5.0 6.4 ± 5.5 0.836
EDSS 2.1 ± 1.3
2.0 [1.0;3.0]$
1.7 ± 1.1
1.5 [1.0;2.0]$
2.4 ± 1.4
2.5 [1.6;3.5]$
<0.001
MSSS 3.5 ± 2.4
3.4 [1.5;5.2]$
2.8 ± 2.0
2.3 [1.3;4.5]$
4.1 ± 2.6
3.9 [2.0;6.0]$
0.003
Relapse rate 0.9 ± 0.6
1.0 [0.5;1.0]$
0.9 ± 0.5
1.0 [0.5;1.0]$
± 0.6
1.0 [0.5;1.0]$
0.317
TC (mg/dl) 201.5 ± 36.5 202.9 ± 34.7 200.5 ± 37.9 0.708
LDL (mg/dl) 126.0 ± 34.1 123.2 ± 33.1 128.1 ± 34.9 0.418
HDL (mg/dl) 57.9 ± 15.2 60.9 ± 17.8 55.7 ± 12.5 0.049
Non HDL (mg/dl) 143.6 ± 37.4 142.0 ± 35.8 144.8 ± 38.9 0.670
Oxidized LDL (u/L) 60.3 ± 24.3 61.0 ± 25.3 59.4 ± 23.9 0.863
TG (mg/dl) 95.3 ± 47.6 102.2 ± 49.5 90.1 ± 45.8 0.149
ApoA1 (mg/dl) 159.1 ± 33.7 173.0 ± 37.6 148.5 ± 26.1 <0.001
ApoB (mg/dl) 90.2 ± 24.7 91.2 ± 22.9 89.5 ± 26.1 0.698
Lp(a) (mg/dl) 29.4 ± 29.5 32.4 ± 29.5 27.5 ± 29.6 0.377
ApoE (mg/l) 77.2 ± 31.8 70.4 ± 29.1 81.9 ± 32.9 0.052
ApoE 3/3 n (%) 98 (73.7) 42 (73.7) 56 (73.7) 0.184
ApoE 4/3 n (%) 20 (15.0) 12 (21.1) 8 (10.5)
ApoE 2/3 n (%) 12 (9.0) 3 (5.3) 9 (11.8)
The continues variables are expressed as mean ± SD; $ median and IQR [].
Categorical variables are expressed as frequency n (%). p represents the significance of the comparison between OC user (OC+) and non-user (OC–) patients (Mann–Whitney test).
EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score; TC, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein TG, triglyceride; Apo
A1, apolipoprotein A1; ApoB, apolipoprotein B; Lp(a), lipoprotein (a) ApoE, apolipoprotein E; ApoE phenotypes (3/3, 4/3,2/3). Analysis of ApoE polymorphism was missing from one
patient and two additional patients carried the E4/E2 phenotype (not shown). Bold values mean significant differences.
FIGURE 1 | Association between Apolipoprotein E phenotypes and disability changes stratified according to oral contraceptive use. Dependence of the Expanded
Disability Status Scale (EDSS) (A) and of the Multiple Sclerosis Severity Score (MSSS) (B) with Apo E phenotypes (ApoEPhen) (2/3, 3/3, 4/3) in oral contraceptive
users (n = 57 in white) and non-users (n = 73 in gray) subgroups of patients. The bars represent inter-quartile range (percentiles 25 and 75); OC+, ApoEPhen 2/3-
only 3 patients analyzed. EDSS and MSSS values are lower in OC users in comparison to non-user patients carrying the E3/E3 phenotype (Mann-Whitney test,
p < 0.001 and p = 0.001, respectively).
model R square = 0.333 (p = 0.016) in OC+ patients; and
to ApoE, [β = 0.024, 95% CI (0.003 to 0.046); p = 0.031];
model R square = 0.299 (p = 0.002) in OC– population (see
Supplementary Material). No significant associations between
the lipids variables and RR were observed using this model (not
shown).
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TABLE 2 | Associations between the lipid profile and clinical variables in patients carrying the E3/E3 phenotype stratified according to oral contraceptive use.
Lipid variables OC+ OC–
RR EDSS MSSS RR EDSS MSSS
TC (mg/dl) −0.034
(0.833)
0.211
(0.180)
0.186
(0.239)
0.283
(0.035)
0.299
(0.025)
0.203
(0.134)
LDL (mg/dl) −0.017
(0.917)
0.363
(0.018)
0.255
(0.103)
0.294
(0.028)
0.246
(0.067)
0.128
(0.346)
Non-HDL (mg/dl) −0.045
(0.778)
0.268
(0.086)
0.152
(0.338)
0.366
(0.005)
0.283
(0.035)
0.221
(0.101)
Apo B (mg/dl) 0.103
(0.517)
0.270
(0.084)
0.313
(0.043)
0.357
(0.008)
0.230
(0.094)
0.199
(0.150)
Apo E (mg/l) −0.001
(0.995)
−0.002
(0.993)
0.030
(0.863)
0.154
(0.266)
0.206
(0.136)
0.356
(0.008)
The results show Spearman Correlation significance between subgroups of patients carrying the E3/E3 phenotype. OC+: oral contraceptives user (n = 36); OC– oral contraceptives
non-user (n = 51); RR, annualized relapse Rate; EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score; TC, total cholesterol; LDL, low density lipoprotein;
HDL, high density lipoprotein; ApoB, apolipoprotein B; ApoE, apolipoprotein E. No significant associations were found for other lipid variables (not shown). Bold values mean significant
differences.
TABLE 3 | Hierarchical multiple linear regression model to determine the
association between lipid variables and disability changes in patients carrying the
E3/E3 phenotype stratified according to oral contraceptive use.
Factors β coefficient* CI 95%* p-value R square Sig
(ANOVA)
DEPENDENT VARIABLE: EDSS
OC+
TC (mg/dl) −0.018 −0.034 to −0.001 0.043 0.328 0.015
LDL (mg/dl) 0.026 0.009 to 0.044 0.005
OC–
ApoE (mg/l) 0.015 0.004 to 0.028 0.012 0.312 0.001
DEPENDENT VARIABLE: MSSS
OC+
LDL (mg/dl) 0.022 0.002 to 0.033 0.011 0.333 0.016
TG/HDL ratio 0.389 0.088 to 0.800 0.048
OC–
ApoE (mg/l) 0.024 0.003 to 0.46 0.031 0.299 0.002
*Adjusted for age, disease onset, disease duration, and oral contraception (OC) intake.
EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Score; Oral
contraceptive users (OC+, n = 34) and non-users (OC–, n = 51) subgroups of
patients carrying the E3/E3 phenotype; TC, total cholesterol; LDL, low-density lipoprotein;
ApoE, apolipoprotein E; TG, triglycerides; HDL, high-density lipoprotein. No significant
associations were found for other lipid variables (not shown). Bold values mean significant
differences.
DISCUSSION
The results reported in this study suggest that oral OC use
modifies the serum lipoprotein profile associated with disability
in patients with MS. Recent prospective studies have shown
variably associations between serum lipid and apolipoprotein
levels and the risk of new lesions accumulation and disability
progression in patients with RRMS and/or the first symptoms
suggestive of the disease (clinical isolated syndrome, CIS)
(2). However, most research has included patients under
immunomodulatory therapies and have not assessed possible
influences of OC use. In consequence, in this cohort, lipid
data was analyzed before the introduction of disease-modifying
therapies and comparing women who never used OC or stopped
its intake before disease onset (OC–) to those who were OC users
after disease onset (OC+).
The serum lipoprotein profile is in part genetically regulated
by the common human isoforms of ApoE designated E2, E3,
and E4, which display different modulatory roles in cholesterol
metabolism, immune function, and neuronal homeostasis (3,
5, 11). In agreement with most studies (4, 5), no association
between the ApoE polymorphism and the clinical activity and
severity of MS was found. However, in individuals carrying
the major E3/E3 phenotype, EDSS and MSSS were significant
lower in the OC+ group, when compared to OC– patients.
In line with previous retrospective work (6, 7) and a recent
longitudinal study (22) no influence of OC use on relapse risk
was observed. Future research in a larger population of carriers
of the ε2 and ε4 alleles is needed. In particular, the apparent
lack of effect on disability in E4/E3 patients is of considerable
interest. In fact, experimental and clinical studies have shown that
the neuroprotective and anti-inflammatory effects of estrogen
are attenuated by the ApoE4 isoform (3) and the risk conferred
by this allele for Alzheimer disease is amplified in women (15).
These results lead us to perform an analyse of serum lipid
variables and their associations with clinical parameters restricted
to carriers of the E3/E3 phenotype.
In healthy women, the use of OC formulations containing
combinations of ethinyl estradiol and a progestin induce in
general an increase of serum TG, ApoA1, and ApoB(11, 12).
Higher levels of HDL and/or of its major apolipoprotein, ApoA1,
were suggested to be protective for the genesis of new lesions in
the MS (23, 24). Although ApoA1 levels were higher in OC+
than in OC– patients, no evidence for a protective effect was
observed in agreement with other studies (25–27). In accordance
with most studies (27), no independent association between
lipid parameters and RR were observed after adjustments in
multivariable analysis. In contrast, when all the variables were
analyzed in a hierarchic model, significant associations were
found between disability and TC, LDL, and the TG/HDL ratio
only in the OC+ population. The TG/HDL ratio is a parameter
recently associated with insulin resistance, obesity, metabolic
syndrome, and clinical outcome in stroke (28). Our finding is
consistent with some studies reporting worsening disability in
patients with high TG levels (24, 26).
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In healthy women, OC intake consistently decreases ApoE
levels and changes the distribution of this protein between
lipoprotein fractions containing ApoB (LDL and triglyceride-rich
lipoproteins) and those devoid of ApoB and rich in ApoA1
(HDL). Interestingly, these alterations are not induced in E4
carriers (12). Recently, differences in LDL particle size were
observed between male and female RRMS patients, supporting
gender differences in lipid metabolism (29). These data indicate
that further work is needed to analyse whether OC intake in
these patients modify ApoE distribution among lipid fractions.
Nevertheless, ApoE levels were lower in OC+ than in OC–
patients, and were correlated in these latter subjects with
disability. Previous studies have linked higher plasma ApoE
levels with severity of EAE (5), higher disability in RRMS (26)
and deep gray matter atrophy in CIS patients (25). Several
experimental studies have shown that oestrogens may modulate
the interactions between Apo E gene expression and LDL
metabolism (3, 13). In this context, it is of great interest
that an altered gene expression for ApoE and other proteins
implicated in cholesterol synthesis and transport occurs during
the development and resolution of CNS lesions in EAE and MS
patients (30, 31). In addition, Mailleux et al. (13) have shown that
LDL receptor deficiency reduces EAE disease severity in female,
but not in male rats, through the induction of ApoE release by
macrophages. In line with the reviewed data, the present results
strongly support a role of sex steroids in modulating ApoE and
related cholesterol metabolism in MS patients.
Beyond the relative small dimension of the cohort, absence
of a healthy control population and its cross-sectional design,
this study has several other limitations. Considering the models
statistical assumptions and the nature of the included clinical
variables, the results should be interpreted carefully. Prospective
studies are necessary to substantiate a causal role of the lipid
profile associated with OC behavior in disability progression. It
should be noted that many patients are at present medicated
following a first clinical episode and paraclinical evidence
suggestive of MS (CIS). Therefore, it is increasingly impractical
or unethical to carry out a study on a larger population of
patients with the diagnosis of RRMS without taking disease-
modifying therapies, which may variably interfere with lipid
metabolism (32, 33). Although a healthy control population has
not be analyzed, as discussed above, our results suggest that
OC intake in these patients and healthy women might interact
with similar pathways of lipid metabolism. Further work is
warranted to investigate this interesting issue. We were unable
to include neuroimaging information, analysis of vitamin D,
and inflammatory markers. In particular, vitamin D levels could
affect the serum lipid profile in MS patients (34) and the mutual
metabolic relationships between oestrogens and vitamin D may
be relevant for the pathogenesis of the disease (1). However,
in a previous work, we have found no evidence for significant
alterations of serum 25-hydroxyvitamin D levels associated with
OC use in these patients (7). Information concerning the intake
of vitamin D supplements was not available. Nonetheless, the
population included in this study was analyzed before the intake
of these supplements became a common practice by these
patients. Dietary and physical activities were not controlled
and the impact of different contraceptive formulations could
not be evaluated. Gava et al. (6) did not find any differences
in the protective effects of OC use in the clinical course of
MS depending on the dose of ethinyl estradiol or the type of
progestin. However, the anti-inflammatory effects of oestrogens
are dose-dependent (8) and future randomized, double-blind,
controlled studies are needed to investigate this issue. The
progestin content of these formulations could change the lipid
profile (11, 12) and were suggested to affect the risk for MS
(35). In conclusion, despite these limitations, our results report
new findings, supporting a role of the serum lipid profile in
mediatingmodulatory effects of sex steroids in the severity ofMS.
In addition, they indicate that further work assessing the effects
of specific OC doses and formulations in lipoprotein metabolism
of these patients may provide new therapeutic strategies for the
disease.
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